Indication: For the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition.

Dosage & Administration: Initial dose is 60 mg in every four hours interval for 21 consecutive days. Oral therapy should be commence within 96 hours of the subarachnoid hemorrhage.

Preparation: Nimocal® Tablet: Each box contains 30 tablets in Alu-Alu blister pack.